Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03901417
Other study ID # 2018P002595
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date June 1, 2019
Est. completion date December 31, 2020

Study information

Verified date January 2020
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Acne scarring is an unfortunate consequence of inflammatory acne vulgaris that often leads to significant cosmetic and psychosocial impacts. Although there have been many advances in the treatment of acne scarring, it remains one of the greatest challenges in cosmetic and laser dermatology.

There have been a multitude of studies establishing the efficacy of non-ablative fractional laser therapy for the treatment of atrophic acne scars, and it is widely regarded as one of the best available treatments. More recently, there has been a renewed interest in controlled, non-thermal dermal injury via microneedling devices in the treatment of atrophic acne scars.

Where there is a gap in the literature, however, is in the evaluation of the combination of non-ablative fractional laser resurfacing with microneedling in the treatment of atrophic acne scars.

The investigators' study will compare the safety and efficacy of using non-ablative fractional laser versus a combination of microneedling and non-ablative fractional laser for atrophic acne scars using a randomized, double-blind, split-face study.

The investigators' aim is to further elucidate the pathogenesis of acne scarring and the best approaches for treatment. In doing so, the investigators will study a combination approach to this complex problem in order to better serve future patients.


Description:

Acne vulgaris is a highly prevalent dermatologic disorder that affects up to 90% percent of the population at some point in their lives to varying degrees. Acne scarring is an unfortunate complication of the inflammation that results if acne is not sufficiently treated. Classically, acne scarring has been described as either atrophic, hypertrophic, keloidal, or pigmented. Atrophic is by far the most common type of acne scarring and is subdivided into boxcar, rolling, and icepick subtypes. The presence of acne scarring has been associated with a significant decrease in patient well-being and has many psychosocial implications. Although the understanding of the pathogenesis, prevention, and treatment of acne scarring has come a long way, there are limitations to the current treatment options and the search for a cure continues.

One of the greatest advances in the treatment of acne scarring came with the advent of non-ablative fractional lasers, which work through the theory of fractional photothermolysis. Fractional photothermolysis relies on the principle of creating thousands of microthermal injury zones in the skin while allowing the surrounding intact skin to expedite wound healing. The relative sparing of the epidermis while facilitating collagen remodeling in the dermis underlies the use of non-ablative fractional laser therapy in the treatment of atrophic scars.

The erbium-doped 1,550-nm non-ablative fractional laser has been extensively studied in the treatment of atrophic acne scars with good efficacy and safety.

The concept of using needle subcision for the treatment of depressed surgical scars was first described by Orentreich et al in 1995. The first microneedling device, a drum-shaped roller was subsequently developed by Fernandes et al in the early 2000s. Several studies have validated the use of microneedling for acne scarring with a similar mechanism of creating microchannels in the dermis that allow for collagen remodeling. Furthermore, microneedling has been demonstrated to induce a specific cytokine profile including fibroblast-like growth factor, vascular endothelial growth factor, epidermal growth factor, and transforming growth factor-beta3 which are associated with favorable wound healing.

More recently, experts have advocated for the use of electric-powered microneedling devices which allow for more controlled injury at a set depth, density, and speed for the treatment of atrophic acne scars with good results.

To the investigators' knowledge, this study will be the first of its kind to compare the efficacy and safety of a combination of 1,550-nm erbium-doped fractional laser and microneedling with the SkinPenTM device to 1,550-nm erbium-doped fractional laser alone in the treatment of atrophic acne scars.

Both treatment modalities in this study are already FDA approved treatment modalities for acne scarring.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 10
Est. completion date December 31, 2020
Est. primary completion date June 30, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- All gender patients

- Age older than 18 years

- Fitzpatrick skin types I-III

- Facial acne scarring of grades III-IV

- Both sides of the face should have similar amount and severity of acne scarring

Exclusion Criteria:

- History of keloidal scarring

- Localized or active infection in the treatment region

- Immunodeficiency disorders

- Porphyria or light sensitivity

- Connective tissue disorders.

- Pregnant or nursing

- Recent isotretinoin use within the past 6 months

- Renal Disease

- Allergies to lidocaine, tetracaine, valacyclovir

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Fraxel Restore (Non-ablative Fractional Laser)
In the study, one side of the face will be treated with non-ablative fractional laser monthly for three months.
Fraxel Restore (Non-ablative fractional laser) and SkinPen (Microneedling Device)
In the study, one side of the face will be treated with a combination of non-ablative fractional laser and microneedling monthly for three months.

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement in acne scarring Two blinded evaluators will use standardized digital photographic review to grade acne scar improvement on a quartile grading scale (1 = 1% to 25%, 2 = 26 to 50%, 3 = 51 to 75%, 4 = >76% improvement). 20 weeks
See also
  Status Clinical Trial Phase
Completed NCT05097157 - Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions N/A
Active, not recruiting NCT01696513 - Effect of Subcision and Suction on Acne Scars N/A
Completed NCT01115634 - Autologous Fibroblast Transplantation in Facial Deformities Phase 2
Completed NCT05254210 - Feasibility Study To Collect Safety And Preliminary Efficacy Data For A Radiofrequency Microneedling Device N/A
Completed NCT05102617 - Post Market Usability Evaluation Of The PicoSure Pro Device N/A
Completed NCT02103816 - The Smartlipo Triplex 1440nm Wavelength Laser and the Sidelaze 800 Hand Piece for the Treatment of Facial Acne Scars N/A
Completed NCT01221922 - Laser Treatment of Acne Scars in Fitzpatrick Skin Types III-VI N/A
Completed NCT03767153 - Clinical Evaluation of Fractional Radiofrequency for the Treatment of Acne Scarring N/A
Completed NCT00974870 - A Pilot Study Testing the Efficacy of a Needling Device for the Treatment of Acne Scars N/A
Not yet recruiting NCT05579171 - Lasers to Aid in Treatment of Acne Scars N/A
Completed NCT02145364 - Ultherapy® for the Treatment of Acne Scars N/A
Not yet recruiting NCT02126657 - The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Acne Scars Phase 2
Enrolling by invitation NCT01847066 - Epidermal Delivery of Ani-Aging Ingredients N/A
Recruiting NCT03850925 - Comparison of Picosecond Pulsed Nd:YAG Laser and Fractional Laser for the Treatment of Acne Scars N/A
Active, not recruiting NCT04807179 - Clinical Study to Evaluate Alexandrite Laser for the Treatment of Acne Scars N/A
Terminated NCT02955381 - Restylane Silk Acne Scar Efficacy Evaluation Study N/A
Completed NCT01213199 - Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars Phase 2
Completed NCT03380845 - Comparison of 1,550-nm Laser and Fractional Radiofrequency Microneedle for the Treatment of Acne Scars in Ethnic Skin N/A
Completed NCT03522922 - Efficacy of Microneedling With Topical Vitamin C in Treatment of Acne Scarring Phase 1/Phase 2
Recruiting NCT05987319 - Feasibility Study to Collect and Assess Safety Data for a Radiofrequency Microneedling Device for Electrocoagulation and Hemostasis of Soft Tissues for Dermatologic Conditions N/A